Smiles: O=C([C@](O1)(O/C=C/[C@@H]([C@H]([C@H]2OC(C)=O)C)OC)C)C(C1=C(C)C3=O)=C(C3=C(O)C(NC(/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@H]2C)=O)=C4N5C=C6)C4=NC5=CC6=C
Inchi: InChI=1S/C43H51N3O12/c1-19-13-15-46-28(17-19)44-32-29-30-37(51)24(6)40-31(29)41(53)43(8,58-40)56-16-14-27(55-9)21(3)39(57-25(7)48)23(5)36(50)22(4)35(49)20(2)11-10-12-26(18-47)42(54)45-33(34(32)46)38(30)52/h10-17,20-23,27,35-36,39,47,49-52H,18H2,1-9H3,(H,45,54)/b11-10-,16-14-,26-12-/t20-,21+,22+,23+,27-,35-,36+,39+,43-/m0/s1
Structural elucidation of the Rifaximin Ph. Eur. Impurity H
Riccardo Stradi, Donatella Nava, Marino Nebuloni, Barbara Pastura, ElenaPini
Journal of Pharmaceutical and Biomedical Analysis Volume 51, Issue 4, 11 March 2010, Pages 858-865
Structure Elucidation of Two Unknown Oxydic Degradation Impurities of Rifaximin
chao liu, chang-qin hu and shao-hong jin
Asian Journal of Chemistry; Vol. 23, No. 7 (2011), 3252-3256
Development and validation of rp-hplc method for the estimation of rifaximin in bulk and in tablet dosage form
T.sudha, P.V.hemalatha, V.R.ravikumar,r.jothi, M.radhakrishnan
Asian Journal of Pharmaceutical and Clinical Research Vol.2 Issue 4, October-December 2009
Stability Indicating HPTLC Method for Analysis of Rifaximin in Pharmaceutical Formulations and an Application to Acidic Degradation Kinetic Study
Kalpana G. Patel , Nitesh R. Jain, and Purvi A. Shah
Hindawi Publishing Corporation ISRN Analytical Chemistry Volume 2013, Article ID 613218, 9 pages